Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDES trial of SLS-005 in adults with spinocerebellar ataxia type 3
2022-501004-10-00Phase 3Completed
- Sponsor
- Seelos Therapeutics, Inc.
- Start
- Jan 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in machado-joseph disease (MJD) comparing SLS-005 0.75 g/kg with Placebo (2 arms). Primary endpoint: Change from baseline in m-SARA total score at Week 52. Started Jan 2023; status: completed.
02
Drugs
trehalose
03
Conditions
machado-joseph disease (MJD)
Beyond the preview
Go deeper on 2022-501004-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501004-10-00.